Premium
Non‐bacterial infections in allogeneic non‐myeloablative stem cell transplant recipients
Author(s) -
Narreddy S.,
MellonReppen S.,
Abidi M.H.,
Klein J.L.,
Peres E.,
Heilbrun L.K.,
Smith D.,
Alangaden G.,
Chandrasekar P.H.
Publication year - 2007
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/j.1399-3062.2006.00172.x
Subject(s) - medicine , fludarabine , cytomegalovirus , hematopoietic stem cell transplantation , cyclophosphamide , aspergillosis , transplantation , total body irradiation , population , stem cell , immunology , chemotherapy , viral disease , herpesviridae , human immunodeficiency virus (hiv) , environmental health , biology , genetics
Data on non‐bacterial infections during allogeneic non‐myeloablative hematopoietic stem cell transplantation (HSCT) are widely different. We evaluated data on 48 consecutive patients who received a conditioning regimen with fludarabine and cyclophosphamide (73%) or fludarabine and total body irradiation (27%) and then underwent allogeneic non‐myeloablative HSCT. Cytomegalovirus (CMV) infection was common and occurred in 48% of patients; 3 patients developed CMV disease, and all survived. CMV reactivation was found to be common with both conditioning regimens in our patient population. Invasive aspergillosis occurred in 4 patients (8%) and 3 died. Other serious non‐bacterial infections were uncommon. Review of the available literature on non‐myeloablative HSCT suggests that the frequency and type of opportunistic infections vary considerably.